



US009211300B2

(12) **United States Patent**
Mayes et al.

(10) **Patent No.:** **US 9,211,300 B2**
(45) **Date of Patent:** **Dec. 15, 2015**

(54) **4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV**

(2013.01); *C07H 19/16* (2013.01); *C07H 19/20* (2013.01); *C07H 19/213* (2013.01)

(71) Applicants: **IDENIX PHARMACEUTICALS, INC.**, Cambridge, MA (US); **Centre National De La Recherche Scientifique**, Paris (FR); **Université Montpellier 2 Sciences et Techniques**, Montpellier (FR)

(58) **Field of Classification Search**
None
See application file for complete search history.

(72) Inventors: **Benjamin Alexander Mayes**, Boston, MA (US); **Adel M. Moussa**, Burlington, MA (US); **Alistair James Stewart**, Lincoln, MA (US); **Gilles Gosselin**, Montpellier (FR)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(73) Assignees: **Idenix Pharmaceuticals LLC**, Cambridge, MA (US); **Centre National De La Recherche Scientifique**, Paris (FR); **Universite Montpellier 2 Sciences et Techniques**, Montpellier (FR)

3,480,613	A	11/1969	Walton et al.
6,174,868	B1	1/2001	Anderson et al.
6,284,458	B1	9/2001	Anderson et al.
6,348,587	B1	2/2002	Schinazi et al.
6,391,542	B1	5/2002	Anderson et al.
6,423,489	B1	7/2002	Anderson et al.
6,433,159	B1	8/2002	Anderson
6,455,513	B1	9/2002	McGuigan et al.
6,566,365	B1	5/2003	Storer
6,573,247	B1	6/2003	McGuigan et al.
6,608,191	B1	8/2003	Anderson et al.

(Continued)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

FOREIGN PATENT DOCUMENTS

CN	1133642	C	1/2004
CN	103848876	A	6/2014

(Continued)

(21) Appl. No.: **14/109,463**

(22) Filed: **Dec. 17, 2013**

(65) **Prior Publication Data**
US 2014/0178338 A1 Jun. 26, 2014

OTHER PUBLICATIONS

U.S. Appl. No. 11/005,443, filed Dec. 6, 2004, LaColla et al.
(Continued)

Related U.S. Application Data

(60) Provisional application No. 61/739,509, filed on Dec. 19, 2012, provisional application No. 61/807,268, filed on Apr. 1, 2013, provisional application No. 61/895,992, filed on Oct. 25, 2013.


Primary Examiner — Travis C McIntosh, III
(74) *Attorney, Agent, or Firm* — Squire Patton Boggs (US) LLP

(51) **Int. Cl.**

<i>C07H 19/00</i>	(2006.01)
<i>A61K 31/70</i>	(2006.01)
<i>C07H 19/10</i>	(2006.01)
<i>C07H 19/20</i>	(2006.01)
<i>C07H 19/213</i>	(2006.01)
<i>A61K 31/708</i>	(2006.01)
<i>A61K 31/7072</i>	(2006.01)
<i>A61K 45/06</i>	(2006.01)
<i>C07H 17/02</i>	(2006.01)
<i>C07H 19/06</i>	(2006.01)
<i>C07H 19/16</i>	(2006.01)
<i>A61K 38/21</i>	(2006.01)
<i>A61K 31/403</i>	(2006.01)
<i>A61K 31/497</i>	(2006.01)
<i>A61K 31/7056</i>	(2006.01)

(57) **ABSTRACT**

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other antiviral agents. In certain embodiments, the compounds are according to Formula 1501:



(1501)

(52) **U.S. Cl.**
CPC *A61K 31/708* (2013.01); *A61K 31/403* (2013.01); *A61K 31/497* (2013.01); *A61K 31/7056* (2013.01); *A61K 31/7072* (2013.01); *A61K 38/21* (2013.01); *A61K 38/212* (2013.01); *A61K 45/06* (2013.01); *C07H 17/02* (2013.01); *C07H 19/06* (2013.01); *C07H 19/10*

or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, R^A, R^B, R^C, L, M and Z are as described herein.

23 Claims, No Drawings